Genacol Pain-Relief

Natural health product licensed in Canada

Other names: Genacol Anti-Douleur
Licence holder: Genacol Group Inc.
NPN or DIN-HM: 80124673
Status: Active licence
Licence date: 26 May 2023
Revision date: 10 February 2026
Form: Capsule
Route of administration: Orale
Application type: Générale (non traditionelle)

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and source	Per dosage unit, according to the source	Maximum per day, adult
Membrane de coquille d'oeuf de poule partiellement hydrolysée Source : Gallus gallus - Coquille d'oeuf	166.667 mg	Not calculated

Non-medicinal ingredients

Gélatine, Cellulose microcristalline, Stéarate de magnésium

Recommended doses in Canada

Population	Age	Quantity per serving	Frequency
Adultes	minimum: 18 years	3 Capsule	1 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Helps to reduce joint pain associated with osteoarthritis. Helps to improve recovery from joint pain and stiffness due to moderate intensity aerobic exercise. Helps to minimize discomfort due to moderate intensity aerobic exercise. Helps reduce levels of CTX-II, a biomarker/marker of cartilage degradation due to moderate intensity aerobic exercise. Helps reduce levels of CTX-II, a biomarker/marker of joint degradation due to moderate intensity aerobic exercise. Starts to reduce joint pain due to moderate intensity aerobic exercise in as little/as quickly as 1 day and joint stiffness in as little/as quickly as 5 days. Clinically proven to provide relief from joint stiffness due to moderate intensity aerobic exercise (in as little as 5-7 days). Helps provide relief from joint pain due to moderate intensity aerobic exercise (as quickly as the first day). Helps reduce levels of CTX-II, a biomarker/marker of joint degradation due to moderate intensity aerobic exercise in postmenopausal women. Helps reduce levels of CTX-II, a biomarker/marker of cartilage degradation due to moderate intensity aerobic exercise in post-menopausal women. Helps to improve recovery from joint pain and stiffness due to moderate intensity aerobic exercise in post-menopausal women. Helps to minimize discomfort due to moderate intensity aerobic exercise in postmenopausal women. Starts to reduce joint pain due to moderate intensity aerobic exercise in as little/as quickly as 1 day and joint stiffness in as little/as quickly as 5 days. Clinically proven to provide relief from joint stiffness due to moderate intensity aerobic exercise (in as little as 5-7 days). Helps provide relief from joint pain due to moderate intensity aerobic exercise (as quickly as the first day). Clinically proven to help reduce joint pain in 7- 10 days. Helps to reduce joint pain and reduce stiffness. Helps to reduce pain associated with osteoarthritis. Helps to reduce joint pain associated with osteoarthritis. Helps to reduce stiffness associated with osteoarthritis. Helps to relieve joint pain and stiffness associated with osteoarthritis. Starts to help reduce joint stiffness due to moderate intensity aerobic exercise as quickly as 5 days.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.